Theratechnologies (NASDAQ:THTX) Stock, Quote.Headers.trade-ideas

Theratechnologies

Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States. It generates revenue from one customer RxCrossroads, which is domiciled in the United States.

THTX

Biotech

News

Health Care

General

Theratechnologies anticipates a temporary supply disruption of Egrifta SV in 2025 due to an FDA-linked manufacturer shutdown, but the company is working to minimize the impact while adjusting revenue projections for 2024.

Theratechnologies Faces Potential Supply Disruption For Its Top Selling Drug, Warns of Revenue Impact Due To Manufacturing Delays

Earnings

Guidance

Movers

Theratechnologies reports Q2 2024 sales of $22.02 million, a 25.5% YoY increase, driven by strong demand for EGRIFTA SV. Net income reached $1 million with an adjusted EBITDA of $5.5 million. The company expects FY 2024 revenue of $87-$90 million and adjusted EBITDA of $13-$15 million.

HIV Medicine Maker Theratechnologies &#39;Wraps Up Strong Second Quarter,&#39; Stock Soars

Penny Stocks

Small Cap

Intraday Update

Markets

Trading Ideas

ACLX

ACXP

AIRE

ALPN

AUDC

AVNW

AWRE

BHIL

CARS

CFLT

CLLS

CNTB

CRAI

CROX

DASH

DRIO

EGHT

ERII

FROG

FSLY

HOWL

HYZN

INFA

JAKK

JOBY

LMDX

LMND

LOCL

LSPD

LYFT

MCRB

NARI

NVST

OLIT

OMCL

OMGA

OPEN

OTLK

PBLA

PCOR

PKOH

PLPC

PLTR

POET

PTVE

PYPL

QCOM

QNST

RCKY

RELY

ROKU

RVLV

SABR

SBGI

SEDG

SGMO

SHOP

STAA

TENB

VIRI

XRAY

Gainers


	OmniLit Acquisition Corp. (NASDAQ: OLIT) jumped 53.2% to $15.53. OmniLit announced that its merger with Syntec was approved by shareholders.


Why STAAR Surgical Shares Are Trading Lower By Around 16%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

Theratechnologies Inc

Press Releases

Theratechnologies Announces Exclusive Licensing Agreement with Ionis to Commercialize Olezarsen and Donidalorsen in Canada

Theratechnologies Announces Preliminary Tolerability and Efficacy Data from Phase 1b, Dose-Ranging Trial of Sudocetaxel Zendusortide in Patients with Advanced Ovarian Cancer

Theratechnologies Receives March 2025 PDUFA Goal Date for Updated Tesamorelin F8 Formulation sBLA

Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment

Theratechnologies Provides Update on EGRIFTA SV® Supply

Theratechnologies Resumes Distribution of EGRIFTA SV®

Theratechnologies to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update

Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2024

Theratechnologies CROI Presentation Highlights Limitations of Using BMI to Assess Cardiovascular (CV) Risk in People with HIV

Theratechnologies Presents Encouraging Virologic Suppression Data from the PROMISE-US Trial of Ibalizumab at CROI

TSX:TH

JonesTrading

Cantor Fitzgerald

Canaccord Genuity

Comments

Theratechnologies

Theratechnologies (NASDAQ:THTX) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga